Cost-effectiveness analysis of second-line medical therapies in acromegaly: a real-life study
Pasireotide was found to be a more cost-effective option in patients with first-line treatment failure.
Authors
- Elena de Dios (ORCID: https://orcid.org/0000-0002-9620-8839)
- Pablo Remón-Ruiz (ORCID: https://orcid.org/0000-0002-4551-8159)
- Andrés Jiménez‐Sánchez (ORCID: https://orcid.org/0009-0009-6130-8184)
- Eva Venegas Moreno (ORCID: https://orcid.org/0000-0001-7093-4990)
- David A. Cano (ORCID: https://orcid.org/0000-0001-6264-3288)
- Alfonso Soto Moreno
- Jorge Alberto Cortés (ORCID: https://orcid.org/0000-0002-0882-9652)
- Celia Hernández-Reina
Institutions
- Instituto de Biomedicina de Sevilla (ES)
- Hospital Universitario Virgen del Rocío (ES)
- Universidad de Sevilla (ES)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-04-28
- DOI
- https://doi.org/10.3389/fendo.2025.1573721
- Citations
- 3
- Primary Topic
- Pituitary Gland Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.88